gsthr logo
Quick links to detailed datasheets for United States of America at gsthr.org

Smoking in United States of America

In the United States of America, smoking is allowed but tobacco products should follow some regulations. Under these regulations, health warnings on tobacco packaging including cigarettes are mandatory, the minimum legal age for their sales is 21 years, and there are no federal legal restrictions on smoking in public places. While tobacco advertising is regulated, not all forms of their advertising are banned. An excise tax of 32.16% with a total taxation rate of 37.36% is applied on cigarettes. Cigarettes can legally be sold with authorised documents. They may also be purchased through vending machines as well as through online channels. Importing cigarettes for trade is allowed with an appropriate import license. Despite these control measures, prevalence data show that smoking remains an important public health issue in the United States. There were 39.8 million current smokers in the country in 2024. This represents an overall adult smoking prevalence of 14.1%, with higher prevalence among men (17.1%) than among women (11.1%). In comparison, the overall current smoking prevalence was 12.3% in 2022. The adult daily smoking prevalence was recorded to be 10.01% in 2020. Smoking-related mortality also remains significant in the country. In 2021, smoking resulted in 360,370 deaths, including 216,986 male deaths and 143,383 female deaths. This shows that smoking accounted for 10.38% of all deaths in the United States in 2021, with a higher rate among men (11.9%) than among women (8.7%).

Read articles from United States of America

November 18, 2026 by acsh.org

Vaping and lung cancer: Here's what we know (and what we don't)

The long-term relationship between vaping and lung cancer remains uncertain, but existing evidence provides important distinctions between e-cigarettes and combustible tobacco.

Research shows that switching completely from smoking to vaping substantially reduces exposure to carcinogenic chemicals, including tobacco-specific nitrosamines. However, decades of follow-up are still needed to establish long-term cancer risks.

The findings reinforce the importance of distinguishing reduced toxicant exposure from proven reductions in disease risk, while recognising the potential role of vaping in tobacco harm reduction.

November 17, 2026 by medicalxpress.com

Smoking in, vaping out: The social trend worrying health experts

Smoking is becoming more socially acceptable, while vaping faces growing disapproval, according to new research involving nearly 20,000 adults across Australia, Canada, England and the United States.

Published in Nicotine & Tobacco Research, the study examined changing attitudes between 2016 and 2022, finding similar trends across all four countries despite differences in vaping regulation.

Researchers warn that these shifting perceptions could discourage smokers from switching to lower-risk alternatives, although the study did not measure actual quitting behaviour. The findings highlight the importance of accurate risk communication in supporting tobacco harm reduction.

November 16, 2026 by clearingtheair.eu

Experts challenge vape exposure claims from bar and mouse studies

Research linking vaping to potential harm among bystanders and children is facing scrutiny over the methods used to assess exposure.

Experts have challenged an Italian indoor air study involving just three vapers, alongside eight mouse studies examining residue from vaping aerosol. Concerns include unrealistic experimental conditions, incomplete exposure measurements and difficulties translating laboratory findings into real-world health risks.

The criticism highlights the importance of rigorous study design and accurate risk communication. Public health conclusions should reflect realistic exposure levels and distinguish between potential hazards and demonstrated health effects.

November 16, 2026 by substack.com

The Double Standard Behind the “False Promise”

The debate over nicotine pouches in New Zealand has exposed an important double standard in tobacco control research.

While critics demand stronger evidence that pouches support smoking cessation, the potential consequences of restricting access receive considerably less scrutiny. Existing research remains limited, but uncertainty about the benefits of nicotine pouches does not establish that prohibition produces better public health outcomes.

A balanced approach should apply the same scientific standards to both harm reduction interventions and restrictive policies, measuring success through actual changes in smoking behaviour and health outcomes.

November 16, 2026 by regulatorwatch.com

Operations Chief on Daily Struggle to Deliver Vapes

Getting vaping products to customers in the United States has become increasingly difficult, with federal shipping restrictions and carrier policies creating significant distribution challenges.

At Mi-Pod Wholesale in Arizona, orders can be prepared within 24 hours, yet finding carriers willing to transport them remains a daily struggle.

These operational barriers raise concerns about the accessibility of regulated, lower-risk nicotine products. Effective tobacco harm reduction requires not only appropriate product standards, but also a workable distribution system that allows responsible businesses to serve adult smokers.

November 12, 2026 by clivebates.com

Evidence sent to the WHO review of nicotine

The WHO's upcoming review of nicotine could have significant implications for the future of tobacco harm reduction.

Following Palau's proposal to bring nicotine under the UN Convention on Psychotropic Substances, a detailed evidence briefing has been submitted to the WHO Expert Committee on Drug Dependence ahead of its critical review in October 2027.

The submission calls for a broader assessment of nicotine science, dependence and public health policy, emphasising the importance of distinguishing nicotine use from the harms of combustible tobacco. International regulatory decisions should consider the potential consequences for smoking cessation and access to lower-risk alternatives.

November 09, 2026 by pouchforum.eu

FDA Recognizes Nicotine Harm Reduction as Brussels Questions Science

The US FDA has authorised 24 additional nicotine pouch products, bringing the total to 67, while explicitly recognising their potential to help adults switch away from more harmful tobacco products.

The decision contrasts with the European Commission's position, which continues to question whether smoke-free nicotine alternatives reduce health risks compared with cigarettes, despite evidence of substantially lower toxicant exposure.

The differing approaches highlight the importance of incorporating relative risk into tobacco regulation. Scientific uncertainty about long-term effects should be acknowledged without overlooking the potential contribution of smoke-free products to tobacco harm reduction.

November 09, 2026 by centerforglobalhealthaccountability.org

Palau and the absurd case for international nicotine prohibition

Palau's proposal to bring nicotine under the UN's international drug control system has raised concerns about the future of tobacco harm reduction.

The initiative seeks a WHO review of nicotine under the Convention on Psychotropic Substances, potentially paving the way for restrictions extending beyond conventional tobacco regulation.

Critics argue that such an approach risks overlooking the significant differences between combustible cigarettes and smoke-free nicotine products. International nicotine policy should distinguish dependence from smoking-related disease and assess whether additional controls would reduce harm or restrict access to lower-risk alternatives.

November 05, 2026 by regulatorwatch.com

FDA Signals PMTA Overhaul, But Will It Deliver?

The FDA's proposed overhaul of its Premarket Tobacco Product Application (PMTA) process has renewed hopes for a more predictable regulatory pathway for vaping products in the United States.

Years of shifting scientific requirements, widespread application denials and regulatory uncertainty have created significant challenges for independent manufacturers. Industry representatives are now calling for clearer approval standards and a workable framework for flavoured e-cigarettes.

The proposed reforms could help strengthen the legal vaping market while supporting tobacco harm reduction. However, their success will depend on whether regulatory changes translate into timely, evidence-based decisions and improved access to lower-risk alternatives for adult smokers.

November 05, 2026 by tobaccoasia.com

US FDA Rethinks the Continuum of Risk

The US FDA is signalling a shift towards recognising the continuum of risk in tobacco and nicotine regulation.

At the Global Tobacco and Nicotine Forum in Lisbon, the agency outlined plans to accelerate product authorisations, reconsider its approach to flavoured e-cigarettes and improve communication about the relative risks of nicotine products.

The proposed changes also place greater emphasis on helping adults who smoke switch to lower-risk alternatives while maintaining safeguards against youth uptake. Integrating tobacco harm reduction into regulatory decisions could represent an important development in US tobacco control policy.